Biotie and Synosia to merge
This article was originally published in Scrip
Executive Summary
Biotie Therapies (Finland) is acquiring CNS drug development firm Synosia Therapeutics (Switzerland) in an all-share deal valued at about €94 million based on Biotie's €0.58 per share price at close on 10 January. The merger will generate a combined company with nine clinical-stage drug candidates.